This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
TD Vaccines A/S
Drug Names(s): ETEC (Enterotoxigenic E Coli) vaccine
Description: The ACE527 ETEC (Enterotoxigenic E Coli) vaccine is a live attenuated oral preparation, comprising three recombinant strains of E.coli.
Deal Structure: ACE527 was originally developed by ACE Biosciences.
In November 2009, Zymenex announced that they have acquired all the shares in ACE Biosciences with the purpose of validating and applying the protein technology of ACE Biosciences on the enzyme-replacement development focus of Zymenex.
Concomitantly with the acquisition of ACE Biosciences, Zymenex - through the ACE Biosciences subsidiary - engaged in a license agreement and collaboration with TD Vaccines. The license agreement concerns ACE527 and ACE920.
Chiesi and Zymenex
In August 2013, Chiesi Group announced that it has signed a definitive agreement with Sunstone Capital to acquire Zymenex Holding A/S and its related group of companies (Zymenex). Terms of the transaction were not disclosed.
In September 2013, Chiesi announced that it has signed a definitive agreement to acquire Zymenex. Terms of the transaction were not disclosed.
Partners: Zymenex A/S
Additional information available to subscribers only: